Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Texas Southwestern Medical Center
This study is a prospective, open-label, single-blind, randomized control study. Study duration is approximately 6 weeks starting at the baseline visit. We will recruit 30 participants (15 per arm) for this pilot study.
Age
20–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 20-65
Can provide informed consent
Confirmed COVID+ test (either rapid antigen or PCR) between 8 weeks and one year prior to initial visit.
Able to consent in English
Endorse symptoms during their initial evaluation and history with the provider that began around the time of the acute COVID19 infection (subjective) including cognitive changes such as cognitive fatigue, brain fog, memory issues,attention issues AND have symptoms in at least 1 out of the 2 following symptom categories:
Clinically significant psychiatric, neurologic, renal, hepatic, opthalmologic, cardiac impairment in the opinion of the investigators, including but not limited to:
Psychiatric:
Acute or chronic unstable Axis I psychiatric illness
History of psychosis
Severe depression Patient Health Questionnaire-9 (PHQ-9) score \>= 20
Suicidality
Neurologic:
Epilepsy
Cognitive dysfunction predating COVID infection
History of delirium
Neurologic conditions with agitation or confusion
Clareo Health | A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid
